Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BI enters into CNS platform/drug collaboration with GSK spin-out Autifony

Executive Summary

Boehringer Ingelheim GMBH entered into an agreement with GlaxoSmithKline PLC spin-out Autifony Therapeutics Ltd. for the exclusive option to acquire Autifony's Kv3.1/3.2 positive modulator platform (includes Autifony's lead compound AUT00206).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies